What is the primary reason for Axon's 8-K filing?

Axon is filing this 8-K to announce that it needs to restate previously issued financial statements for the fiscal year ended December 31, 2024, and the quarters ended March 31, 2024, and September 30, 2024, due to an error in the balance sheet presentation of its convertible senior notes.

What specific financial statements are being restated?

The audited consolidated financial statements as of and for the fiscal year ended December 31, 2024, and the unaudited condensed consolidated financial statements for the quarterly periods ended March 31, 2024, and September 30, 2024, are being restated.

What was the nature of the financial reporting error?

The error involved the misclassification of Axon's $690.0 million aggregate principal amount of 0.50% convertible senior notes due 2027. These notes should have been presented as current liabilities instead of long-term liabilities because the company's stock price met certain thresholds making them convertible at the holders' option.

Does this restatement affect Axon's overall financial performance or equity?

According to Axon, the error only impacts the presentation of the convertible notes between current and long-term liabilities on the balance sheet. It did not affect Total Assets, Total Liabilities, Stockholders' Equity, or the statements of operations, cash flows, or stockholders' equity for the affected periods.

What are the implications for Axon's internal controls?

The restatement highlights an additional material weakness in Axon's internal control over financial reporting (ICFR). This weakness relates to the lack of effective controls to periodically monitor contingent conversion provisions of the convertible notes and their impact on liability classification. This adds to a previously identified material weakness in revenue recognition.

AXON 8-K: Earnings & Results & Financial Events

01—Abstract

Summary

Summary of the 8-K filed May 7, 2025. Cited figures are marked; the original filing is the authoritative source.

Axon Enterprise, Inc. (AXON) has filed an 8-K report on May 7, 2025, primarily addressing a restatement of previously issued financial statements.

The company's Audit Committee, in consultation with management, determined that its audited consolidated financial statements for the fiscal year ended December 31, 2024, and unaudited condensed consolidated financial statements for the quarters ended March 31, 2024, and September 30, 2024, should no longer be relied upon due to an error in the balance sheet presentation of its 0.50% convertible senior notes due 2027. The error involved the misclassification of these notes, amounting to $690.0 million^a, from current liabilities to long-term liabilities on the balance sheet. This reclassification is due to the notes becoming convertible at the option of holders during the applicable subsequent calendar quarters because the company's stock price met certain thresholds.

Importantly, Axon states that this reclassification does not impact total assets, total liabilities, equity, or the statements of operations, cash flows, or equity. The company plans to amend its Form 10-K for the fiscal year ended December 31, 2024, to reflect these restated financials.

02—Key points

Key Highlights

Axon is restating previously issued financial statements for the fiscal year ended December 31, 2024, and the quarters ended March 31, 2024, and September 30, 2024.
The restatement is due to an error in the balance sheet presentation of its $690.0 million convertible senior notes due 2027.
The error involved misclassifying the notes from current liabilities to long-term liabilities.
Axon states the reclassification does not impact Total Assets, Total Liabilities, Stockholders' Equity, or the statements of operations, cash flows, or equity.
The restatement is linked to a material weakness in internal control over financial reporting (ICFR) related to monitoring contingent conversion provisions of the convertible notes.
Previously identified material weakness in ICFR related to revenue recognition also remains.
The company will file an amended Form 10-K to include the restated financial information.

03—Questions

Frequently Asked Questions

What is the primary reason for Axon's 8-K filing?
Axon is filing this 8-K to announce that it needs to restate previously issued financial statements for the fiscal year ended December 31, 2024, and the quarters ended March 31, 2024, and September 30, 2024, due to an error in the balance sheet presentation of its convertible senior notes.
What specific financial statements are being restated?
The audited consolidated financial statements as of and for the fiscal year ended December 31, 2024, and the unaudited condensed consolidated financial statements for the quarterly periods ended March 31, 2024, and September 30, 2024, are being restated.
What was the nature of the financial reporting error?
The error involved the misclassification of Axon's $690.0 million aggregate principal amount of 0.50% convertible senior notes due 2027. These notes should have been presented as current liabilities instead of long-term liabilities because the company's stock price met certain thresholds making them convertible at the holders' option.
Does this restatement affect Axon's overall financial performance or equity?
According to Axon, the error only impacts the presentation of the convertible notes between current and long-term liabilities on the balance sheet. It did not affect Total Assets, Total Liabilities, Stockholders' Equity, or the statements of operations, cash flows, or stockholders' equity for the affected periods.
What are the implications for Axon's internal controls?
The restatement highlights an additional material weakness in Axon's internal control over financial reporting (ICFR). This weakness relates to the lack of effective controls to periodically monitor contingent conversion provisions of the convertible notes and their impact on liability classification. This adds to a previously identified material weakness in revenue recognition.

04—Continue

← View all 8-K filings